Kristen Kluska

Roy Buchanan

Matthew Herm

- Intelligent Bio Solutions Inc. (IBIO) added **33 new customer accounts** during its fiscal first quarter ended September 30, 2025, representing a **50% increase** compared to the same period the prior year.  **[1420720_adb4d246af44405e8c3659d1d4459d6e_0]** 
- This expansion brings the company's total active accounts to **over 480**.  **[1420720_adb4d246af44405e8c3659d1d4459d6e_0]** 
- Growth was particularly strong in the **United Kingdom**, with **91% of new accounts** being first-time adopters, and included entry into new sectors such as government administration.  **[1420720_adb4d246af44405e8c3659d1d4459d6e_1]**

Intelligent Bio Solutions Adds 33 New Customer Accounts in Fiscal Q1 2026

- iBio, Inc. announced new preclinical data from an obese non-human primate (NHP) study for its **IBIO-610** candidate, an Activin E antibody, on **October 30, 2025**.  **[1420720_0001420720-25-000033_ibio-20251030xex99d1.htm:0]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:1]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:2]** 
- The study demonstrated an extended half-life of **33.2 days in NHPs** for IBIO-610.  **[1420720_0001420720-25-000033_ibio-20251030xex99d1.htm:0]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:1]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:2]** 
- Based on allometric scaling, the predicted human half-life for IBIO-610 is **up to 100 days**, suggesting potential for dosing as infrequently as **twice per year**.  **[1420720_0001420720-25-000033_ibio-20251030xex99d1.htm:0]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:1]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:2]** 
- These findings, which underscore IBIO-610's potential as a next-generation therapy for obesity and cardiometabolic disease, will be presented at ObesityWeek® 2025 from **November 4–7, 2025**.  **[1420720_0001420720-25-000033_ibio-20251030xex99d1.htm:0]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:1]** **[1420720_0001420720-25-000033_ibio-20251030x8k.htm:2]**

iBio (IBIO)